Get the Stockscreener App
916.31
1.47%
13.29
After Hours:
916.30
-0.010
-0.00%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $916.31, with a volume of 2.19M.
It is up +1.47% in the last 24 hours and down -10.94% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$903.02
Open:
$912.49
24h Volume:
2.19M
Relative Volume:
0.71
Market Cap:
$818.26B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
40.56
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-0.19%
1M Performance:
-10.94%
6M Performance:
+28.23%
1Y Performance:
+7.50%
1-Day Range:
$909.09
$922.15
1-Week Range:
$895.61
$926.77
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
916.31 | 806.39B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.93 | 566.67B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.18 | 362.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.37 | 287.71B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
187.14 | 288.11B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley - TipRanks
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer? - Insider Monkey
Assessing Eli Lilly (LLY) Valuation After The Recent Share Price Pullback - simplywall.st
Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide? - Benzinga
Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com
AI Models Split on Eli Lilly: Strong Growth vs. Premium Valuation - TipRanks
Spartan Planning & Wealth Management Buys Shares of 1,556 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Dynamic Advisor Solutions LLC - MarketBeat
Biocon To Benefit After Eli Lilly Joins Novo Nordisk To Exit European Insulins Market - NDTV Profit
INNOVENT BIO-Eli Lilly Strategic Collaboration Deal Takes Effect; Rumored Acquisition Intent Not True - AASTOCKS.com
Eli Lilly to phase out select insulin products across Europe by 2027 - MSN
Workforce was region’s secret weapon in winning Eli Lilly | Opinion - PennLive.com
Martin Shkreli Says Silicon Valley's Hottest Health Obsession Is A 'Delusion' - Benzinga
Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study - TipRanks
Barclays Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - TipRanks
Clark Foundation, Lilly to partner on new downtown basketball court - Indianapolis Business Journal
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 - Benzinga
Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order - Fierce Pharma
Eli Lilly (NYSE:LLY) Sees Institutional Activity in Russell 1000 - Kalkine Media
Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform - Insider Monkey
Gradient Investments LLC Buys 19,634 Shares of Eli Lilly and Company $LLY - MarketBeat
Hutchens & Kramer Investment Management Group LLC Sells 3,715 Shares of Eli Lilly and Company $LLY - MarketBeat
Grove Bank & Trust Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by Sarasin & Partners LLP - MarketBeat
Nordea Investment Management AB Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Stock: Analysts See 35% Upside, Driven by GLP-1 Demand and Q4 2025 ResultsNews and Statistics - IndexBox
What's going on with Eli Lilly on Monday? - MSN
Eli Lilly's diabetes drug cuts weight by 17% in trial - qz.com
Eli Lilly Weight Loss Push Weighs On Valuation And Growth Hopes - simplywall.st
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Lilly, Amgen Seek Fast Win in Suit Over Clinics in Discount Plan - Bloomberg Law News
Eli Lilly selects Lehigh Valley for $3.5 billion life sciences plant in 2026 - Lehigh Valley Business
What's Going On With Eli Lilly On Monday? - Benzinga
Eli Lilly (LLY) Faces Negative ROE Trend Despite Promising Future - GuruFocus
Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10 - TipRanks
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum - CNBC
Takeda, Lilly Rejected by Supreme Court on Actos Fraud Lawsuit - Bloomberg.com
Here's How Much Upside Eli Lilly Stock Has, According to Analysts - AOL.com
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
AI Models Split on Eli Lilly: Growth Strength vs. Premium Valuation - TipRanks
Lehigh Valley planners to discuss traffic, other potential issues with proposed Eli Lilly plant - The Morning Call
Procyon Advisors LLC Has $7.77 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Aventura Private Wealth LLC Buys Shares of 3,861 Eli Lilly and Company $LLY - MarketBeat
GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug - The Daily Upside
Eli Lilly Bets Billions on Asian Expansion with Major China Push - ad-hoc-news.de
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Insider Monkey
Eli Lilly President discusses steps to further strengthen ‘Make in India’ with Piyush Goyal - The Indian EYE
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Eli Lilly (LLY) Downgraded by HSBC Amid Valuation Concerns - GuruFocus
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):